Abvc Biopharma (ABVC) Short term Debt (2010 - 2026)

Abvc Biopharma (ABVC) has reported Short term Debt for 11 consecutive years, with $59462.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short term Debt fell 93.18% year-over-year to $59462.0; the trailing twelve-month figure through Jun 2026 stood at $59462.0 (down 93.18% YoY), and the FY2025 full-year result was $755512.0, down 10.09% from the prior year.
• Short term Debt fell to $59462.0 in Q2 2026 per ABVC's latest filing, from $88737.0 in the prior quarter.
• Across five years, Short term Debt topped out at $1.9 million in Q4 2022 and bottomed at $59462.0 in Q2 2026.
• Historically, Short term Debt has averaged $805840.3 across 5 years, with a median of $847000.0 in 2024.
• The sharpest annual moves came in 2022 and 2026: Short term Debt climbed 15.47% in 2022, then tumbled 93.18% in 2026.
• Over 5 years, Short term Debt stood at $1.9 million in 2022, then plunged by 52.51% to $899250.0 in 2023, then declined by 6.56% to $840252.0 in 2024, then decreased by 10.09% to $755512.0 in 2025, then slumped by 92.13% to $59462.0 in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $59462.0, $88737.0, and $755512.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.